Global Stem Cells Group and Bioheart announce the launch of a unique clinical trial called "Adipose Derived Cells for Chronic Obstructive Pulmonary Disease."
Global Stem Cells Group, Inc. and BioHeart, Inc. announce the launch of a clinical trial for the treatment of Chronic Obstructive Pulmonary Disease (COPD) using adipose-derived stem cell technology. The clinical trials will be held at the Global Stem Cells treatment center in Cozumel, Mexico, as well as in several U.S. states. Global Stem Cells Group affiliate Cellgenic in collaboration with CMC Hospital of Cozumel offer cutting-edge cellular medicine treatments to patients from around the world.
The study titled "An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered intravenously in Patients with Chronic Obstructive Pulmonary Disease" is lead by principal investigator Armando Pineda Velez, Global Stem Cells Group Medical Director. Global Stem Cells Group has represented that it offers the most advanced protocols and techniques in cellular medicine from around the world.
The Cozumel clinical trials will be lead by Rafael Moguel, M.D., an advocate and pioneer in the use of stem cell therapies to treat a wide variety of conditions.
COPD is one of more than 150 chronic conditions that are treatable with adult stem cells, eliminating the potential risk of surgery, transplants, and toxic drugs
Details of the protocol and eligibility criteria can be found on the government clinical trial website at: http://www.clinicaltrials.gov.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group's corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG's six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments
Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.
Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.